Zoetis Inc. (ZTS) finds itself in an interesting spot. The animal health giant has built a reputation for developing innovative products that veterinarians actually want to use, but right now it's dealing with a problem that no amount of R&D excellence can immediately fix: a pair of osteoarthritis drugs that have become lightning rods for criticism.

The Analyst's Perspective

KeyBanc Capital Markets launched coverage of Zoetis this week with a Sector Weight rating, which in analyst-speak means "good company, but we're not rushing to recommend it." The reasoning comes down to a few specific concerns that analyst Steve Dechert laid out pretty clearly.

First, there's the osteoarthritis pain franchise. Zoetis's monoclonal antibody products for OA pain—Librela for dogs and Solensia for cats—were supposed to be blockbusters. Instead, they've become the subject of heavy social media criticism due to their potential side effects. When pet owners start sharing concerns online about drugs affecting their animals, that creates a headwind that's hard to quantify but impossible to ignore.

Dechert acknowledges that Zoetis has a strong track record of developing innovative products. The issue isn't capability; it's timing. The analyst wants to see either new product launches that can move the revenue needle or a meaningful turnaround in the OA pain franchise before getting more enthusiastic about the stock.

Competition Heating Up

Beyond the osteoarthritis troubles, KeyBanc expects increased competition hitting Zoetis's dermatology and parasiticide segments. Recent product launches from competitors are making these once-comfortable market positions a bit more contested.

That said, this isn't a company in crisis. KeyBanc describes Zoetis as a high-quality business with revenue growth rates above the industry average and historically strong profit margins. The company also sports a solid balance sheet, pays a dividend, and runs a significant stock buyback program. These are the hallmarks of a well-managed operation.

Valuation And Recent Performance

Here's where things get interesting from a valuation perspective. Zoetis shares are currently trading at roughly 17.5 times forward earnings, which represents a notable discount to the company's two-year average of around 27 times. That compression tells you the market is pricing in concerns about near-term growth.

The company's third-quarter results illustrated the challenge. Zoetis reported sales of $2.4 billion, up 1% year over year but slightly below the consensus estimate of $2.41 billion. Growth in parasiticides, diagnostics, and key dermatology products was essentially offset by declines in those problematic mAb products for osteoarthritis pain.

At the time of publication on Friday, Zoetis shares were trading up 4.19% at $120.75, suggesting investors may be finding value at current levels even as analysts remain cautious about the near-term catalyst picture.

The Bottom Line

KeyBanc's initiation essentially says: Zoetis is a fundamentally strong company trading at a reasonable price, but we need to see proof that it can navigate through current headwinds before getting more bullish. The OA pain franchise needs a reset, competition is intensifying, and the pipeline needs to deliver. Until those things happen, it's a wait-and-see situation for one of animal health's biggest players.